FDA clearance is a critical regulatory milestone that can significantly impact a biotech company's valuation and investor perception. For Cullinan Oncology, this clearance not only validates the potential of CLN-619 but also enhances its credibility and attractiveness to investors. Given the high unmet medical need in relapsed/refractory multiple myeloma, this development could lead to increased investor interest and a positive short-term impact on CGEM's stock price.